Physician profile
Tosal Saxena
NPI 1295591345
$990.33
in general payments reported to CMS, 2019-2025
16 companies · $522 in 2025
The $522 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $469 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $183.58 | 2025 | Nemluvio |
| Abbvie INC. | $160.07 | 2024-2025 | |
| Ucb, INC. | $132.60 | 2024-2025 | Bimzelx |
| Janssen Biotech, INC. | $78.60 | 2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $69.15 | 2024 | Sotyktu |
| Pfizer INC. | $65.70 | 2024-2025 | |
| Leo Pharma INC. | $52.18 | 2025 | Adbry |
| Mayne Pharma Commercial LLC | $51.90 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $35.93 | 2025 | Dupixent |
| Genzyme Corporation | $31.06 | 2025 | |
| Sanofi Pasteur INC. | $30.07 | 2024 | |
| Sun Pharmaceutical Industries INC. | $28.12 | 2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $21.07 | 2024 | Cabtreo |
| Novartis Pharmaceuticals Corporation | $18.19 | 2025 | |
| Incyte Corporation | $16.57 | 2024 | Opzelura |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $15.54 | 2025 | Fanapt, Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tosal Saxena listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.